Nebenwirkungen · Advate
ADVATE 250 IU/2 ml powder and solvent for solution for injection ADVATE 500 IU/2 ml powder and solvent for solution for injection ADVATE 1 000 IU/2 ml powder and solvent for solution for injection ADVATE 1 500 IU/2 ml powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 19
HOS-112464 · Präparat HOS-093675
Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with factor VIII, including with ADVATE (see section 5.1). If such inhibitors occur, the condition will manifest itself as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre be contacted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-23T12:20:00Z · SHA-256 1676714d819bb0bd275e9f7e4eb6349a64035cde34acd2a9aa639c8e0ad4123b · Passage f06b45045f417730383e320dc0593e627bcd4f8e9122ba4859504fa5a07527e9 · Zeichen 812–1155 im Abschnitt